Product Information
KETOROLAC 30 MG/ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $1.0175 per ML under NDC 63323016212. Its NADAC has been published 439 times since Aug 2, 2017.
FDA first approved this application on Jan 11, 2002. Its Orange Book therapeutic-equivalence code is AP.
Strength
30 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323016212
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR
Effective Date
9/23/2026
Active Ingredients
KETOROLAC TROMETHAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA075784FDA Approved
1/11/2002
TE Code
AP
On Market Since
10/18/2000
Pharmacological Classes
Price Statistics
The NADAC for KETOROLAC 30 MG/ML VIAL has been published 439 times since Aug 2, 2017, and over the history we have for it it has declined 70.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0175 per ML |
|---|---|
| All-time high | $3.4756 (Aug 16, 2017) |
| All-time low | $0.7047 (Mar 18, 2026) |
| 52-week high | $1.0778 |
| 52-week low | $0.7047 |
| Median price | $1.3842 |
| Average price | $1.5008 |
| Largest weekly change | +53.5% (Apr 22, 2020) |
| Weeks tracked | 439 |
| Tracking since | Aug 2, 2017 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 46% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
KETOROLAC TROMETHAMINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cyclooxygenase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KETOROLAC 30 MG/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for KETOROLAC 30 MG/ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $1.0175 per ML (NDC 63323016212), effective Sep 30, 2026.
How has the price of KETOROLAC 30 MG/ML VIAL changed over time?
Over the history we have for it, the NADAC for KETOROLAC 30 MG/ML VIAL has declined 70.7%. It has been tracked across 439 weekly CMS publications since Aug 2, 2017.
What are the highest and lowest recorded NADAC prices for KETOROLAC 30 MG/ML VIAL?
Since Aug 2, 2017, the NADAC for KETOROLAC 30 MG/ML VIAL has ranged from a low of $0.7047 (Mar 18, 2026) to a high of $3.4756 (Aug 16, 2017), with a median of $1.3842 per ML.
Are there cheaper alternatives to KETOROLAC 30 MG/ML VIAL?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, KETOROLAC 60 MG/2 ML VIAL, is $0.5524 per ML — about 46% below KETOROLAC 30 MG/ML VIAL.
Who manufactures KETOROLAC 30 MG/ML VIAL?
KETOROLAC 30 MG/ML VIAL (NDC 63323016212) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.